Cytoreason expands reach to leverage machine learning in drug development in South Korea

Computational illness modeling firm Cytoreason Ltd. is increasing its reach into Asia with a current partnership with South Korean large knowledge firm Helixrus Inc., which is targeted on organic large knowledge and multiomics. The alliance will give attention to leveraging Helixrus’ deep information of the South Korean pharmaceutical market, and in depth community of relationships in Asian markets, to spotlight Cytoreason’s capabilities in prioritizing new targets, discovering biomarkers, profiling combos, stratifying sufferers and different use instances inside the drug lifecycle.BioWorld MedTech Deals and M&A Drugs Artificial intelligence Digital well being Asia-Pacific

Recommended For You